Substantial doubt about the company's ability to continue as a going concern.
“As a result of our recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Entrada Therapeutics expects four significant clinical readouts through the first half of 2027, including Vertex's DM1 interim results and three DMD data releases, while cash is expected into Q4 of 2027.
Entrada Therapeutics held $193.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, expected to fund operations into the fourth quarter of 2027. It disclosed substantial doubt about continuing as a going concern within 12 months.
Entrada Therapeutics reported $193.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, supporting operations into Q4 2027. Third-quarter net loss was $39.7 million.
Entrada Therapeutics reported favorable safety and tolerability for ENTR-601-45 at 5 mg/kg, with a 0.10% mean dystrophin increase and 0.15% mean exon-skipping increase versus baseline in Cohort 1; no functional benefit was observed.
